Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)

• Published in: Journal of headache and pain Vol. 23; no. 1; pp. 10 - 8
• Main Authors: Johnston, Karissa, Harris, Linda, Powell, Lauren, Popoff, Evan, Coric, Vladimir, L’Italien, Gilbert, Schreiber, Curtis P.
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01.12.2022; Springer Nature B.V; BMC
• Subjects: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; CGRP; Double-Blind Method; Drug treatment; Drug use; Epidemiology; Headache; Humans; Internal Medicine; Medicine; Medicine & Public Health; Migraine; Migraine Disorders - drug therapy; Neurology; Pain management; Pain Medicine; Piperidines; Prescription drugs; Pyridines; Quality of Life; Research Article; Systematic review; Treatment Outcome; CGRP; Migraine; Drug treatment; Quality of life

Background The objective of this study was to describe patterns in monthly migraine days (MMD) and tablet utilization, and to estimate health-related quality of life (HRQoL) measures in patients treated as needed (PRN) with rimegepant 75 mg over 52-weeks. Methods Eligible subjects were adults with ≥...